An Artificial Neural Network-Based Drug Proarrhythmia Assessment Using Electrophysiological Characteristics of Cardiomyocytes |
Yoo, Yedam
(Dept of IT Convergence Engineering, Kumoh National Institute of Technology)
Jeong, Da Un (Dept of IT Convergence Engineering, Kumoh National Institute of Technology) Marcellinus, Aroli (Dept of IT Convergence Engineering, Kumoh National Institute of Technology) Lim, Ki Moo (Dept of Medical IT Convergence Engineering, Kumoh National Institute of Technology) |
1 | Hwang M, Lim C-H, Leem CH, Shim EB, "In silico models for evaluating proarrhythmic risk of drugs", APL Bioeng., 2020;4(2):021502, doi:10.1063/1.5132618. DOI |
2 | Simundic AM, "Measures of Diagnostic Accuracy: Basic Definitions", Ejifcc, 2009:19(4);203-211. |
3 | Roden DM, "Cellular basis of drug-induced torsades de pointes", Br. J. Pharmacol., 2008;154:1502-1507, doi:10.1038/bjp.2008.238. DOI |
4 | Shah RR, "Drugs, QTc interval prolongation and final ICH E14 guideline: An important milestone with challenges ahead", Drug Saf., 2005;28(11):1009-1028, doi:10.2165/00002018- 200528110-00003. DOI |
5 | Cavero I, Crumb W, "ICH S7B draft guideline on the nonclinical strategy for testing delayed cardiac repolarisation risk of drugs: A critical analysis", Expert Opin. Drug Saf., 2005;4(3):509-530, doi:10.1517/14740338.4.3.509. DOI |
6 | Strauss DG, et al., "Comprehensive In Vitro Proarrhythmia Assay (CiPA) Update from a Cardiac Safety Research Consortium / Health and Environmental Sciences Institute / FDA Meeting", Ther. Innov. Regul. Sci., 2019;53(4):519-525, doi: 10.1177/2168479018795117. DOI |
7 | Colatsky T, et al., "The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative - Update on progress", J. Pharmacol. Toxicol. Methods, 2016;81:15-20, doi:10.1016/j.vascn.2016.06.002. DOI |
8 | Dutta S, et al., "Optimization of an in silico cardiac cell model for proarrhythmia risk assessment", Front. Physiol., 2017;8:1-15, doi:10.3389/fphys.2017.00616. DOI |
9 | Li Z, et al., "Assessment of an In Silico Mechanistic Model for Proarrhythmia Risk Prediction Under the CiPA Initiative", Clin. Pharmacol. Ther., 2019:105(2):466-475, doi: 10.1002/cpt.1184. DOI |
10 | Llopis-Lorente J, Gomis-Tena J, Cano J, Romero L, Saiz J, Trenor B, "InSilico Classifiers for the Assessment of Drug Proarrhythmicity", J. Chem. Inf. Model., 2020;60(10):5172-5187, doi:10.1021/acs.jcim.0c00201. DOI |
11 | Chang KC, et al., "Uncertainty quantification reveals the importance of data variability and experimental design considerations for in silico proarrhythmia risk assessment", Front. Physiol., 2017;8:1-17, doi:10.3389/fphys.2017.00917. DOI |
12 | Li Z, et al., "General Principles for the Validation of Proarrhythmia Risk Prediction Models: An Extension of the CiPA In Silico Strategy", Clin. Pharmacol. Ther., 2020;107(1):102-111, doi:10.1002/cpt.1647. DOI |
13 | Ismail WN, Hassan MM, Alsalamah HA, Fortino G, "CNNbased health model for regular health factors analysis in internetof-medical things environment", IEEE Access, 2020;8:52541-52549, doi:10.1109/ACCESS.2020.2980938. DOI |
14 | Lancaster MC, Sobie EA, "Improved Prediction of Drug-Induced Torsades de Pointes Through Simulations of Dynamics and Machine Learning Algorithms", Clin. Pharmacol. Ther., 2016;100(4):371-379, doi:10.1002/cpt.367. DOI |
15 | O'Hara T, Virag L, Varro A, Rudy Y, "Simulation of the undiseased human cardiac ventricular action potential: Model formulation and experimental validation", PLoS Comput. Biol., 2011;7(5), doi:10.1371/journal.pcbi.1002061. DOI |